Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
November 4, 2021

Infectious disease trials have highest increase of delayed start date since 2016

This year has seen the highest number of infectious disease trials with delayed start dates than at any point in the last five years.

By GlobalData Healthcare

Rescue clinical trials, specifically those that have delayed initial start date, often need rescuing for many reasons, such as resources becoming scarce and the impact of the Covid-19 pandemic. GlobalData’s Pharmaceutical Intelligence Centre has compiled data on rescue trials, noticing a trend in delayed initial trial start dates.

Trials with delayed initial start dates have increased steadily since 2016, with the most being this year with 5,578. Looking by therapy area, oncology had the most clinical trials in that period with 7,753 trials, followed by the central nervous system and infectious diseases to round out the top three. But when looking at percentage increases over the past five years, infectious disease was the highest at 198%, followed by the central nervous system at 123% and musculoskeletal disorders at 106%. Oncology had the fourth highest percentage increase with 98%. Lastly, the number of trials with a delayed start date for infectious disease doubled between 2019 and last year. This may be due to companies focusing on vaccines and therapeutics for Covid-19. A further breakdown can be seen in Figure 1.

As trends show, the number of trials with delayed initial start dates will continue to rise. This may be due to the rising number of Covid-19 cases due to its variants, which will create more obstacles for companies to overcome.

Related Companies

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU